



Revista Portuguesa de Pneumologia

ISSN: 0873-2159

sppneumologia@mail.telepac.pt

Sociedade Portuguesa de Pneumologia
Portugal

Sahin, H.; Naz, I.; Varol, Y.; Aksel, N.; Tuksavul, F.; Ozsoz, A.
COPD patients with severe diffusion defect in carbon monoxide diffusing capacity predict
a better outcome for pulmonary rehabilitation
Revista Portuguesa de Pneumologia, vol. 22, núm. 6, noviembre-diciembre, 2016, pp. 323
-330
Sociedade Portuguesa de Pneumologia
Lisboa, Portugal

Available in: <http://www.redalyc.org/articulo.oa?id=169749132004>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative



ORIGINAL ARTICLE

COPD patients with severe diffusion defect in carbon monoxide diffusing capacity predict a better outcome for pulmonary rehabilitation



H. Sahin^a, I. Naz^b, Y. Varol^{c,*}, N. Aksel^c, F. Tuksavul^a, A. Ozsoz^c

^a Dr Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Pulmonary Rehabilitation Unit, Izmir, Turkey

^b Katip Celebi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation

^c Dr Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Izmir, Turkey

Received 7 November 2015; accepted 6 March 2016

Available online 25 April 2016

KEYWORDS

6-Minute walk test;
Pulmonary
rehabilitation;
Pulmonary function
tests;
DLCO;
Quality of life;
Dyspnea

Abstract

Purpose: The aim of this study was to compare the effects of pulmonary rehabilitation (PR) on six-minute walk test (6mWT) between chronic obstructive pulmonary disease (COPD) patients with moderate or severe carbon monoxide diffusion defects. We also evaluated dyspnea sensation, pulmonary functions, blood gases analysis, quality of life parameters and psychological symptoms in both groups before and after pulmonary rehabilitation.

Methods: Patients with COPD underwent a comprehensive 8-week out-patient PR program participated in this study. Patients grouped according to diffusion capacity as moderate or severe. Outcome measures were exercise capacity (6mWT), dyspnea sensation, pulmonary function tests, blood gases analysis, quality of life (QoL) and psychological symptoms.

Results: A total of 68 patients enrolled in the study. Thirty-two (47%) of them had moderate diffusion defect [T_{LCO} ; 52 (47–61) mmol/kPa] and 36 (53%) of them had severe diffusion defect [T_{LCO} ; 29 (22–34) mmol/kPa]. At the end of the program, PaO_2 ($p=0.001$), Modified Medical Research Council dyspnea scale ($p=0.001$), 6mWT ($p<0.001$) and quality of life parameters improved significantly in both groups ($p<0.05$). Also the improvement in DL_{CO} ($p=0.04$) value and FEV₁% ($p=0.01$) reached a statistically significant level in patients with severe diffusion defect. When comparing changes between groups, dyspnea reduced significantly in patients with severe diffusion defect ($p=0.04$).

* Corresponding author.

E-mail address: yeldavatansever@hotmail.com (Y. Varol).

Conclusion: Pulmonary rehabilitation improves oxygenation, severity of dyspnea, exercise capacity and quality of life independent of level of carbon monoxide diffusing capacity in patients with COPD. Furthermore pulmonary rehabilitation may improve DL_{CO} values in COPD patients with severe diffusion defect.

© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Chronic obstructive pulmonary disease (COPD) is defined by airflow limitation and is a complex pathological condition. COPD is associated with an important reduction in physical activity that contributes to the patient's disability and poor health-related quality of life. Pulmonary rehabilitation (PR) is aimed to eliminate or at least attenuate these difficulties.^{1,2} Therefore, PR has been recommended as an integral part of management for patients with COPD.^{3,4} However, the responses to PR may vary significantly among individuals. Although there are many studies mentioning changes of FEV1, FVC, FEV1/FVC after PR, in some studies, significant changes in forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC values were not detected after PR.^{5–8}

The diffusing capacity for carbon monoxide (DL_{CO}) is a common and clinically useful test that provides a quantitative measure of gas transfer in the lungs.⁹ The decrease in DL_{CO} , one of the first signs of disease progression, can point out the arterial O_2 desaturation during exercise. For COPD patients with low DL_{CO} values pose a high risk for poor survival.¹⁰ Although PR is known to have many effects on functional outcomes of COPD patients, there is not enough information about the diffusion capacity in terms of PR outcome.² Also in a recent study authors suggest that diffusing capacity was the strongest predictor of exercise capacity in all subjects with COPD.¹¹ Therefore can CO diffusion capacity be used to evaluate which patient will benefit more from PR program? Moreover will there be a significant change in CO diffusion capacity after PR program in patients with COPD?

The aim of our study was to compare the results of PR program on exercise capacity (6mWT) between COPD patients with moderate and severe diffusion defect detected by DL_{CO} . Our secondary aims were comparing the results of the program on arterial blood gas analysis, dyspnea sensation, exercise capacity, quality of life and psychological symptoms between two groups.

Methods

We conducted a prospective cohort study to compare the effectiveness of exercise training in COPD patients with moderate and severe diffusion defect. The study was approved by the local institutional review board. Patients included in the study completed an informed written consent form.

Subject selection

We recruited COPD patients diagnosed according to Global initiative for Chronic Obstructive Lung Disease (GOLD) definition, stable from exacerbations (with no worsening of respiratory symptoms, no increase in the use of rescue medication, and no unscheduled visits due to COPD worsening) for at least 4 weeks. All patients were suffering from dyspnea, reduced exercise tolerance and limitation of daily living activities. The recruitment criteria included a minimum age of 40 years old, a history of 10 or more pack-years of smoking, a FEV1 of less than 80% of the predicted value after bronchodilator use and a ratio of FEV1 to FVC of 0.7 or less after bronchodilator use.¹² The condition of the patients was graded according to the stages of disease defined by the GOLD.¹³ The patients' self-reported respiratory symptoms, medications, smoking history, and coexisting medical conditions were documented at the beginning of the study. Comorbid diagnoses were established using the clinical history and physical examination findings during the visit and were supported by a review of the available medical records. We excluded patients who were suffering from acute exacerbation, history of other lung diseases, (pneumoconiosis, pulmonary tuberculosis, interstitial lung disease); and orthopedic, neurologic, or cardiovascular impairment that might render the subject incapable of completing the exercise training. Also subjects with lack of motivation, poor compliance (not attending the program more than 2 times) or having transport problems were excluded from the study. We grouped patients; those with diffusion capacity between 41 and 60% of predicted as moderate (group 1) and under 40% of predicted as severe (group 2) diffusion defect.¹⁴

Measurement of pulmonary parameters and questionnaires

All patients underwent cardiac and respiratory system examinations and were evaluated by chest X-rays and blood gases analysis. Pulmonary functions were assessed by measuring body plethysmography (Zan 500, Germany) and carbon monoxide diffusing capacity test (Zan 300, Germany). The DL_{CO} maneuver begins with a full exhalation to residual volume (RV), the mouthpiece is then connected to the test gas (0.3 percent carbon monoxide [CO], 10 percent helium), and the subject inhales rapidly to total lung capacity. Following a 10 s breath hold, the subject exhales quickly and completely to RV. An alveolar sample of the exhaled gas

is then analyzed for calculation of the dilution of helium and the uptake of CO. Dyspnea was assessed by Modified Medical Research Council (MMRC) dyspnea scale and modified BORG scales.³ Quality of life was assessed using disease specific St. George Respiratory Questionnaire and SF-36 health related quality of life questionnaire.^{15,16} Psychological symptoms were assessed by Hospital Anxiety and Depression Questionnaires.^{17,18} 6-Minute walking test was used which was defined by American Thoracic Society (ATS) standards.¹⁹ All measurements were assessed at admission and at the end of the PR.

Pulmonary rehabilitation parameters

Patients underwent an 8-week hospital based out-patient pulmonary rehabilitation program twice a week in our hospital's Pulmonary Rehabilitation Unit. Pulmonary rehabilitation was completely tailored to suit the needs of the individual. PR program consists of education, supervised exercise training, nutritional intervention and psychological counseling, if needed. Exercises were chosen for each patient for their ability to tolerate exercise and their disease severity. Exercises included; breathing exercises, treadmill (at least 15 minutes) and cycle training (at least 15 minutes), peripheral muscle training, and stretching exercises. Also we informed patients about medication advices, bronchial hygiene techniques, energy conservation, relaxation techniques for reducing dyspnea and home exercises.³ After respiratory physiotherapy education, upper and lower extremity stretching and strengthening exercises were performed. All strengthening exercises were started without a weight. During PR program according to the BORG scale⁴⁻⁶ half a kilogram weight is added in every 4 periods of exercises. The treadmill and bicycle/arm ergometer were used for aerobic exercises. We calculated both workloads for cycling and walking speed for treadmill from six minutes' walk test.⁴ Treadmill walking speed is calculated by 80% of average 6MWT speed using formula: (6mWT distance \times 10)/1000 km/h. Cycling workload was calculated with the formula (Watt = 103.217 + (30.500 \times Sex) + (-1.613 \times age) + [(0.002 \times distance \times weight)] sex; male = 1 female = 0). Patients were trained at 60–90% of maximum heart rate. Also we used BORG dyspnea scores for regulation of exercise.³⁻²⁰ Exercise intensity increased according to the patient progress. During exercise we used pulse oximetry to supervise patients and if the SpO₂ fell below 90% oxygen supplementation was provided.

Statistical analysis

We performed statistical analyses using the SPSS 17.0 (Statistical Package for the Social Sciences, Chicago, Illinois). Descriptive statistics were performed for all the recorded variables. The normality of the data was evaluated by Kolmogorov Smirnow test. We used Mann Whitney-U test to compare baseline characteristics and changing outcomes as shown Δ values before and after PR. We used Wilcoxon test to compare variables between before and after PR. $p < 0.05$ value is considered as significant.




Fig. 1 Exercise capacity (6 minute walk test) of the patients before and after pulmonary rehabilitation ($p < 0.05$ for within group change, $p = 0.16$ between groups).

Results

Demographic data

A total of 68 patients (61 men %90) participated in this study. Thirty-two (47%) patients had moderate diffusion defect [T_{LCO} ; 57 (47–61) mmol/kPa] (group 1) and 36 (53%) patients had severe diffusion defect [T_{LCO} ; 29 (22–34) mmol/kPa] (group 2). All patients had smoking history. Groups were similar in terms of age, gender and cigarette consumption ($p > 0.05$). Body mass index (BMI) was significantly lower in patients with severe diffusion defect ($p < 0.05$).

Initial measurements before PR

When comparing initial measurements; exercise capacity, quality of life, FEV₁, FEV₁/FVC, PaO₂, SaO₂ were significantly lower in group 2 ($p < 0.05$) before PR in comparison with group 1 (Table 1). Also dyspnea sensation and anxiety levels were significantly higher in group 2 compared with group 1 before PR.

Initial measurements after PR

After PR program there was a statistically significant increase in 6mWT in both groups (401–443 m for group 1, 328–388 m for group 2, $p < 0.001$, both) (Fig. 1). In both groups PaO₂ significantly increased after rehabilitation ($p < 0.05$, both). After rehabilitation, significant improvement recorded in dyspnea sensation (mMRC scores) and SGRQ scores (–9 for group 1, –7 for group 2) in both groups ($p < 0.05$) (Table 2). There was no significant difference in both groups in term of Δ FEV₁/FVC, Δ IC, Δ VC, Δ pH, Δ PaCO₂, Δ Role emotional scores (SF-36) and Δ mental health score (SF-36) after PR program.

Differences between groups 1 and 2

When comparing changes between groups; in group 1 the average change in 6mWT was 40 (min 21, max 50) meters, while in group 2 the change was 50 (min 30, max 70) meters

Table 1 Baseline demographic and clinical features of patients.

Variable	Group 1 (n = 32)	Group 2 (n = 36)	p
Age (years)	60 (55, 66)	63 (57, 67)	0.168
BMI (kg/m ²)	28 (26, 31)	23 (20, 28)	0.001
Male gender n (%)	30 (93.8)	31 (86.1)	0.434
Smoking (p/years)	50 (33, 70)	50 (47, 80)	0.308
FEV ₁ (% predicted)	48 (37, 63)	34 (25, 50)	0.003
FEV ₁ /FVC	64 (54, 72)	51 (41, 65)	0.000
IC (% predicted)	69 (41, 86)	47 (37, 65)	0.052
VC (% predicted)	70 (56, 77)	58 (46, 79)	0.212
DLCO	57 (47–61)	29 (22–34)	0.000
pH	7.41 (7.39, 7.43)	7.40 (7.38, 7.43)	0.912
PaO ₂	72 (67, 83)	68 (58, 75)	0.020
PaCO ₂	39 (38, 43)	42 (36, 47)	0.483
SaO ₂	95 (93, 96)	93 (90, 95)	0.009
6MWD (meters)	414 (352, 464)	340 (300, 380)	0.001
ΔBORG	1 (0.5, 2)	2 (1, 3)	0.014
MMRC	3 (2, 3)	4 (3, 4)	0.000
HADa	5.5 (3, 8)	9 (6, 14)	0.002
HADd	5 (3, 9)	7.5 (5, 11)	0.095
SGRQ			
Symptom	48 (30, 58)	67 (51, 79)	0.000
Activity	55 (42, 67)	73 (59, 92)	0.000
Impact	40 (27, 46)	49 (35, 69)	0.005
Total	46 (31, 55)	60 (46, 72)	0.000
SF36			
Physical functioning (PF)	60 (40, 85)	45 (20, 65)	0.023
Social functioning (SF)	87 (62, 100)	62 (25, 75)	0.004
Role physical (RF)	25 (0, 100)	0 (0, 50)	0.151
Role emotional (RE)	66 (0, 100)	33 (0, 100)	0.091
General health (GH)	52 (30, 67)	35 (20, 52)	0.024
Mental health (MH)	76 (64, 88)	64 (50, 76)	0.066
Bodily pain (BP)	74 (42, 100)	52 (32, 88)	0.038
Vitality (VT)	55 (45, 80)	50 (29, 60)	0.020

Data are expressed as median (interquartile range) or %, BMI: body mass index, FEV₁: forced expiratory volume in the 1 s, FVC: forced vital capacity, IC: inspiratory capacity, VC: vital capacity, PaCO₂: partial arterial carbon dioxide pressure. SaO₂: arterial oxygen saturation, 6MWD: six minutes walk distance, MMRC: Medical Research Council Dyspnea Scale, HAD: Hospital Anxiety and Depression Scale, SGRQ: St. George Respiratory Questionnaire, SF-36: Short-Form Health Survey.

(Table 2). There was no significant difference between groups in terms of 6mWT change. The changes in PaO₂ levels were significantly higher in group 2, compared to group 1 (Table 2). Improvement of dyspnea sensation was significantly higher in patients with severe diffusion defect compared to group 1 ($p=0.04$) (Table 2). There was no difference in SGRQ scores, SF-36 and HAD scores between groups 1 and 2 comparing changes in QoL parameters ($p>0.05$) (Table 2). In addition; FEV₁% and DLCO increased in patients with only severe diffusion defect ($p<0.05$) (Table 2).

Discussion

In this study we found significant improvement in oxygenation (PaO₂), severity of dyspnea, exercise capacity and quality of life parameters in patents with moderate and severe diffusion defect after PR program. Additionally FEV₁ and DLCO increased significantly in patients with severe diffusion defect. When comparing changes between groups;

improvement in dyspnea sensation was significantly higher in patients with severe diffusion defect.

All studies about effects of pulmonary rehabilitation on lung function have investigated FEV₁, FVC, FEV₁/FVC and blood gas analysis. There are few studies conducted on investigating the effect of PR program on different DLCO groups.^{21,22} COPD is characterized by high morbidity and mortality. It remains unknown which aspect of lung function carries the most prognostic information. In a study of 604 COPD patients which were clinically stable it was concluded that DLCO was the most powerful predictor of survival.²³ In another study in patients with COPD it was emphasized that FEV₁, IC and DLCO were higher predictive regarding exercise capacity and DLCO was the strongest predictor.¹¹ In a 5-year follow up study it was found that decline in 12-minute walk test was mainly explained by deterioration in DLCO and this measurements at baseline were the most important predictors of declining exercise capacity in COPD patients.²⁴

Single measurements of DLCO in patients with COPD have shown that a reduced value in early disease is associated

Table 2 Comparison of changes in exercise capacity, dyspnea, pulmonary functions, blood gas analyses, quality of life and psychological symptoms between two groups.

Outcomes	Group 1 (n = 32)	Group 2 (n = 36)	p
$\Delta 6MWD$ (meter)	40 (21, 50)*	50 (30, 70)*	0.160
$\Delta BORG$	-0.05 (-1.0)	-0.05 (-1.5, 0)*	0.587
$\Delta MMRC$	0 (-1.0)*	-1 (-1.0)*	0.044
ΔFEV_1 (% predicted)	1.5 (-2.7, 6.5)	3 (-1, 6.8)*	0.413
$\Delta FEV_1/FVC$	0 (-8.7, 3.7)	-0.5 (-5, 9.5)	0.214
ΔIC (% predicted)	2 (-16.5, 15)	2 (-9, 30)	0.513
ΔVC (% predicted)	5 (-4.5, 11.5)	3 (-9, 18)	0.212
$\Delta DLCO$ (% predicted)	-1 (-7, 7.5)	7.5 (-4, 13)*	0.019
ΔpH	0.001 (-0.01, 0.02)	0.005 (-0.02, 0.03)	0.965
ΔPaO_2 (mmHg)	4 (1, 9)*	7.5 (3, 11)*	0.035*
$\Delta PaCO_2$ (mmHg)	0 (-4.5, 4.7)	-0.5 (-5.5, 1)	0.235
ΔSaO_2	1 (0, 2)*	1 (0, 3)*	0.656
SGRQ			
Δ Symptom	-7 (-15, 5)	-8 (-15, 1)*	0.495
Δ Activity	-7 (-18, -0.03)*	-6 (-18, 0.2)*	0.901
Δ Impact	-8 (-18, -3)*	-7 (-17, 0.8)*	0.636
Δ Total	-9 (-15, -2)*	-7 (-15, -3)*	0.953
SF-36			
Δ Physical functioning (PF)	5 (-10, 30)*	5 (0, 21)*	0.979
Δ Social functioning (SF)	0 (0, 25)	12 (0, 25)*	0.401
Δ Role physical (RF)	5 (-10, 30)*	0 (0, 50)*	0.946
Δ Role emotional (RE)	0 (0, 33)	0 (0, 66)	0.586
Δ General health (GH)	7.5 (-4, 16)*	5 (-5, 17)*	0.746
Δ Mental health (MH)	0 (-8, 8)	2 (-9, 16)	0.838
Δ Bodily pain (BP)	0 (-10, 20)	5 (0, 34)*	0.293
Δ Vitality (VT)	5 (-5, 25)	10 (0, 25)*	0.424
$\Delta HAD_{anxiety}$	-1.5 (-4, 0.2)	-3 (-5, -1)*	0.069
$\Delta HAD_{depression}$	0 (-3, 2.2)	-2 (-5, 0.2)*	0.075

Data are expressed as median (interquartile range), Results are shown as change between post-treatment and baseline levels (Δ values).

* $p < 0.05$ for within group change, 6MWD: six minutes walk distance, MMRC: Medical Research Council Dyspnea Scale, FEV₁: forced expiratory volume in the 1 s, FVC: forced vital capacity, IC: inspiratory capacity, VC: vital capacity, DLCO: carbon monoxide diffusing capacity, PaO₂: partial arterial oxygen pressure, PaCO₂: partial arterial carbondioxide pressure, SaO₂: arterial oxygen saturation, SGRQ: St. George Respiratory Questionnaire, SF-36: Short-Form Health Survey, HAD: Hospital Anxiety and Depression Scale.

with accelerated decline in FEV1 and in advanced disease it predicts exercise capacity and mortality. In population studies a reduced DLCO predicts all-cause mortality more strongly than a reduced FEV1. It also stated that repeated measurements of CO transfer in individuals were needed to increase the present poor knowledge of the natural history of the contribution of alveolar disease to the progression of COPD.²⁵ In a study performed in heavy smokers lower diffusing capacity was found to be directly correlated with decline FEV1/FVC ratio and a greater progression of CT – quantified emphysema.²⁶ Mohsenifar et al. demonstrated that patients with reduced DLCO, particularly when <20% of predicted, were more likely to have reduced PaO₂ at rest and were more likely to require supplemental oxygen with low levels of activity. They pointed out DLCO was useful in evaluating whether supplemental oxygen is required for exercise.²⁷ In our study, consistent with the other studies, FEV1, FEV1/FVC, PaO₂, SaO₂, exercise capacity and quality of life scores were significantly lower in patients with severe diffusion defect before pulmonary rehabilitation.

Pulmonary rehabilitation has emerged as a recommended standard of care for patients with chronic lung disease.^{1,28} It

has been demonstrated to improve exercise capacity, reduce symptoms of dyspnea and increase health-related quality of life.^{28,32} Pulmonary function tests showed different results after pulmonary rehabilitation in previous studies. In most of them, significant changes in FEV1, FVC and FEV1/FVC values^{5–8} were not detected. Because rehabilitation is a multicomponent intervention the results are controversial. In a study of 24 patients with COPD who carried out at least half an hour of pranayama breathing exercises for 3 months, despite significant increase in PEF values, there was no significant increase in FEV1 and FVC.³³ Cecily et al. had observed that as well as FEV1 and FVC the value of PEFR (peak expiratory flow rate) significantly had increased in 100 patients with COPD.³⁴ Shebl et al. concluded that FEV1 increased only in severe COPD but FVC and FEV1/FVC ratio was increased in the medium and severe COPD after the supervised two- month home based exercise program. However, these increases were not statistically significant.³⁵ In a study comparing differences of improvement by gender, FEV1 and FVC increased in both; however they were greater in males after pulmonary rehabilitation program.³⁶ When 225 patients were assessed according to severity of

COPD; FEV1 increased significantly in stage 3 and 4, VC (vital capacity) increased significantly to 2.3 and 4, TLC (total lung capacity) decreased significantly only in stage 3, RV (residual volume) were significantly decreased in stage 3 and 4 after pulmonary rehabilitation program.³⁷ Unlike other studies, after pulmonary rehabilitation for 3 years, there was not a significant fall in FEV1 at the end of the 3rd year.³⁸

Changes in arterial blood gas were evaluated less and the results vary in previous studies. In some of the studies PaO₂, PaCO₂ and SaO₂ did not change^{6,29} but in some other studies both PaO₂ and SaO₂ increased significantly after pulmonary rehabilitation.^{21–39} A study that assessed blood gas analysis according to severity of COPD showed that PaO₂ increased significantly with stage 3 and 4, PaCO₂ decreased significantly in stage 4 diseases after PR.³⁷ There are few studies evaluating changes in diffusing capacity after PR. In a previous study conducted in our clinic there was a significant increase in DL_{CO} level after 8 week outpatient rehabilitation program in 44 patients with COPD.²¹

Zanini et al. divided moderate to severe COPD patients (*n*: 75) into two groups depending on the change in 6MWT (responders >30 m and no responders ≤30 m). They showed that FEV₁ <50% pred. and TLC <50% pred. were independent predictors of PR efficacy. They also found that complex COPD patients with poor lung function got more benefit from PR.³⁹ Sixty patients were stratified into subgroups according to airway obstruction (FEV₁ ≥ or <50% predicted), pulmonary hyperinflation (TLC > or < or =120% predicted), BMI value (BMI > or < or =25), cardiovascular (CV) comorbidity, and resting PaO₂ (PaO₂ ≥ or <60 mmHg) levels, suggesting that subjects with poorer exercise capacity or quality of life had greater room for improvement.⁴⁰ An observational study, which included 102 COPD patients who followed PR showed that patients with worse disease status (i.e. a combination of lower FEV₁, more hyperinflation, lower exercise capacity and worse quadriceps force) improved most in endurance exercise capacity.⁴¹ Our results were similar to the results of these studies; although it did not reach statistical difference, there was an improvement in the exercise capacity of the patients with severe diffusion defect when comparing with the patients having moderate diffusion defect. It is possible that the improvement in 6MWT partially reflects the gain in DLCO and lung function or simply reflects the fact that subjects with worse COPD have more room for improvement than those with mild COPD. It may also indicate that emphysematous COPD subjects have a better chance of improvement from rehabilitation than chronic bronchitis. In addition, PaO₂ and O₂ saturation values were significantly increased in both groups with a little difference in favor of the patients with severe diffusion defect. In COPD patients, exercise capacity may decrease as a result of exercise intolerance, ventilation and gas exchange impairment, cardiac failure and pulmonary muscle dysfunction or combination of them. Hypoxia due to gas exchange dysfunction may directly or indirectly decrease exercise tolerance.²⁰ DL_{CO} which is a good predictor of gas exchange dysfunction can also predict exercise restriction perfectly.¹¹ Older textbooks suggest that thickening of the alveolar-capillary membrane (in interstitial lung disease) and loss of alveolar membrane surface area (in emphysema) are the primary causes of a low DLCO.⁴² However, new experimental data suggest that diseases that influence the DLCO do so by

reducing the volume of red blood cells in the pulmonary capillaries.⁴³ In healthy adults total volume of blood in lungs is less than 150 ml at rest.⁴³ Diseases which reduce alveolar-capillary surface area cause a reduction in the blood volume in the lungs. The blood volume in the pulmonary capillaries and the DLCO are increased during exercise.⁴² Therefore, we hypothesizes that the increase in DLCO after PR may be due to the recruitment of pulmonary capillaries after exercise.

Patients with severe diffusion defects usually avoid exercise in daily life. However, PR program including aerobic and reinforcement exercise combination may improve their muscle power, exercise performance and quality of life, and may give them the courage to compete with their dyspnea symptom.⁴⁴ Improvement in DLCO and FEV1 in this group of patients may reflect the success in muscle exercise as a result of recruitment of pulmonary capillaries. Also by breathing exercises it is possible that the exercise may reverse some dead space ventilation, and make new areas of alveolar more available to gas exchange.

Seventy-four stable COPD patients were grouped according to MMRC dyspnea scale and evaluated after PR. There was an improvement in 6-minute walking test and SGRQ only in the patients with dyspnea score: grade 1/2 and grade 3/4 while the improvement in grade 5 patients was very limited. The authors suggested that baseline state is a poor predictor of response to rehabilitation.⁴⁵ Despite that, in our study, baseline DLCO levels were good predictors for better PR outcome. Although the MMRC and BORG scores were higher in patients with severe diffusion defect, these scores significantly decreased after PR. Also walking distance within group 2 (not statistically significant between groups) was increased significantly after PR. When the two groups were compared in terms of MMRC and BORG dyspnea score changes, the augmentation of MMRC and BORG score was significantly higher in patients with severe diffusion defect. Additionally, anxiety score was the only parameter decreased in patients with moderate diffusion defect whereas both anxiety score and depression score were decreased in patients with severe diffusion defect.

Conclusion

We concluded that pulmonary rehabilitation improves oxygenation, severity of dyspnea, exercise capacity and quality of life in patients with COPD independent of carbon monoxide diffusion capacity levels. Furthermore pulmonary rehabilitation may improve DLCO and FEV1 values in COPD patients with severe diffusion defect. However long-term follow up studies are needed to have the best results from rehabilitation programs.

The authors have no declarations of interest to report.

Ethical responsibilities

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflict of interest

The authors have no conflict of interest.

References

1. Santus P, Bassi L, Radovanovic D, Airoidi A, Raccanelli R, Triscari F, et al. Pulmonary rehabilitation in COPD: a reappraisal (2008–2012). *Pulm Med.* 2013;2013:374283.
2. Bailey KL. The importance of the assessment of pulmonary function in COPD. *Med Clin North Am.* 2012;96:745–52.
3. Spruit M, Singh S, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An Official American Thoracic Society/European Respiratory Society Statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med.* 2013;188:13–64.
4. Luxton N, Alison JA, Wu J, Mackey MG. Relationship between field walking test and incremental cycle ergometry in COPD. *Respirology.* 2008;13:856–62.
5. Lan CC, Chu WH, Yang MC, Lee CH, Wu YK, Wu CP. Benefits of pulmonary rehabilitation in patients with COPD and normal exercise capacity. *Respir Care.* 2013;58:1482–8.
6. Karapolat H, Gürgün A, Eyigör S, Ekren PK, Kirazlı Y. Effect of short-term pulmonary rehabilitation on pulmonary function tests, blood gases, functional capacity, dyspnea, quality of life and psychological symptoms in chronic pulmonary diseases: a retrospective study. *Turk J Phys Med Rehabil.* 2010;56:6–10.
7. Karapolat H, Atasever A, Atamaz F, Kirazlı Y, Elmas F, Erdinç E. Do the benefits gained using a short-term pulmonary rehabilitation program remain in COPD patients after participation. *Lung.* 2007;185:221–5.
8. Román M, Larraz C, Gómez A, Ripoll J, Mir I, Miranda EZ, et al. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial. *BMC Fam Pract.* 2013;11:14–21.
9. Hughes JMB. The single breath transfer factor (TL CO) and the transfer coefficient (KCO): a window onto the pulmonary micro-circulation. *Clin Physiol Funct Imaging.* 2003;23:63–71.
10. Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. *Medicine (Baltimore).* 2014;93:76.
11. Farkhooy A, Janson C, Arnardóttir RH, Malinovschi A, Emtner M, Hedenström H. Impaired carbon monoxide diffusing capacity is the strongest predictor of exercise intolerance in COPD. *COPD.* 2013;10:180–5.
12. Quenjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of European Respiratory Society. *Eur Respir J Suppl.* 1993;16:5–40.
13. GOLD Executive Committee. Global strategy for diagnosis, management and prevention of COPD [updated 2009; accessed 2010 July 1]. Available from: <http://www.golcopd.com>.
14. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J.* 2005;26:948–68.
15. Polatlı M, Yorgancıoğlu A, Aydemir Ö, Yılmaz DN, Kırkıl G, Atış Naycı S, et al. Validity and reliability of Turkish version of St. George's respiratory questionnaire. *Tuberc Torax.* 2013;61:81–7.
16. Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş A. Validity and reliability of Turkish version of Short form SF-36. *Turk J Drugs Therapeut.* 1999;12:102–6.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67:361–70.
18. Aydemir Ö. Hastane Anksiyete ve Depresyon Ölçeği Türkçe formunun geçerlilik ve güvenilirlik çalışması. *Türk Psikiyatri Dergisi.* 1997;8:280–7.
19. ATS statement: guidelines for the six-minute walk test. *Am J Respir Care Med.* 2002;166:111–7.
20. ATS/ERS statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med.* 2006:390–413.
21. Sahin HD, Naz I, Aksel N, Demir A, Tuksavul F, Ozsoz A. Outcomes of pulmonary physiotherapy and rehabilitation program applied to patients with chronic pulmonary disease. *Türkiye Klinikleri Arch Lung.* 2014;15:47–53.
22. Zanini A, Chetta A, Gumiero F, Patrona SD, Casale S, Zampogna E, et al. Six-minute walking distance improvement after pulmonary rehabilitation is associated with baseline lung function in complex COPD patients: a retrospective study. *BioMed Res Int.* 2013:483162.
23. Boutou AK, Shrikrishna D, Tanner RJ, Smith C, Kelly JL, Ward SP, et al. Lung function indices for predicting mortality in COPD. *Eur Respir J.* 2013;42:616–25.
24. Farkhooy A, Janson C, Arnardóttir RH, Emtner M, Hedenström H, Malinovschi A. Impaired carbon monoxide diffusing capacity is the strongest lung function predictor of decline in 12 minute-walking distance in COPD; a 5-year follow-up study. *COPD.* 2014;10 [epub ahead of print].
25. Osmanliev DP, Joyce H, Watson RA, Pride NB. Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease. *Respir Med.* 2005;99:1053–60.
26. Mohamed Hoesein FA, Zanen P, van Ginneken B, van Klaveren RJ, Lammers JW. Association of the transfer coefficient of the lung for carbon monoxide with emphysema progression in male smokers. *Eur Respir J.* 2011;38:1012–8.
27. Mohsenifar Z, Lee SM, Diaz P, Criner G, Sciruba F, Ginsburg M, et al. Single-breath diffusing capacity of the lung for carbon monoxide: a predictor of PaO₂, maximum work rate, and walking distance in patients with emphysema. *Chest.* 2003;123:1394–400.
28. Ries AL. Pulmonary rehabilitation: summary of an evidence-based guideline. *Respir Care.* 2008;53:1203–7.
29. Marciniuk DD, Brooks D, Butcher S, Debigare R, Dechman G, Ford G, et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. *Can Respir J.* 2010;17:159–68.
30. Gloeckl R, Marinov B, Pitta F. Practical recommendations for exercise training in patients with COPD. *Eur Respir Rev.* 2013;22:178–86.
31. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med.* 2006;173:1390–413.
32. Rochester CL. Exercise training in chronic obstructive pulmonary disease. *J Rehabil Res Dev.* 2003;40:59–80.
33. Katiyar SK, Bihari S. Role of Pranayama in Rehabilitation of COPD patients – a Randomized Controlled Study. *Indian J Allergy Asthma Immunol.* 2006;20:98–104.
34. Cecily HSJ, Alotaibi AA. Effectiveness of breathing exercises on pulmonary function parameters and quality of life of patients with chronic obstructive pulmonary disease. *IJHSR.* 2013;3:80–5.
35. Shebl A, Fadila D. Impact of pulmonary rehabilitation program on health outcomes of patients with chronic obstructive pulmonary disease. *J Educ Pract.* 2013;4:78–86.

36. Emery CF, Leatherman NE, Burkner EJ, MacIntyre NR. Psychological outcomes of a pulmonary rehabilitation program. *Chest*. 1991;100:613–7.
37. Takigawa N, Tada A, Soda R, Takahashi S, Kawata N, Shibayama T, et al. Comprehensive pulmonary rehabilitation according to severity of COPD. *Respir Med*. 2007;101:326–32.
38. Stav D, Raz M, Shpirer I. Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. *BMC Pulm Med*. 2009;30:9–26.
39. Sarpkaya U, Tuna H, Tabakoglu E, Altıay G. Effects of ventilatory muscle training and aerobic exercise program in chronic obstructive pulmonary disease on quality of life. *Turk J Phys Med Rehab*. 2005;51:14–8.
40. Vagaggini B, Costa F, Antonelli S, Simone CD, Cusatis GD, Martino F, et al. Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD. *Respir Med*. 2009;103:1224–30.
41. Altenburg WA, De Greef MH, ten Hacken NH, Wempe JB. A better response in exercise capacity after pulmonary rehabilitation in more severe COPD patients. *Respir Med*. 2012;106:694–700.
42. Macintyre N, Crapo RO, Viegi G, Jhonson DC, van der Griten CPM, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J*. 2005;26:720.
43. McCormack MC. Diffusing capacity for carbon monoxide. Up-to-date. Last updated July 16; 2015.
44. AACVPR guidelines for pulmonary rehabilitation programmes. 3rd ed. Human Kinetics; 2005.
45. Garrod R, Marshall J, Barley E, Jones PW. Predictors of success and failure in pulmonary rehabilitation. *Eur Respir J*. 2006;27:788–94.